Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Vivus gets development & marketing rights to Tanabe's TA-1790

29 Mar 2018

Executive Summary

Vivus (sexual dysfunction products) has licensed worldwide development and marketing rights--excluding Japan, China, and specific Pacific Rim countries--to Tanabe Seiyaku's (cardiovascular diseases) Phase I phosphodiesterase type 5 (PDE5) inhibitor TA-1790 (avanafil). The drug candidate treats male and female sexual dysfunction through oral and local administration.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By